Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Multimodal AI Supports Prostate Cancer Risk Assessment Across Diverse Cohorts

By LabMedica International staff writers
Posted on 29 Sep 2026

Artera’s (Los Altos, CA, USA) multimodal artificial intelligence (MMAI) platform is being featured in five abstracts at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting. More...

The studies assess its use across prostate cancer populations in Australia, India, Africa, and the U.S., focusing on treatment decisions, metastatic risk, and consistency across patient groups.  

One study from the prospective ASTuTE trial evaluated how MMAI affected decisions about short-term androgen deprivation therapy (ADT) in 786 men with intermediate-risk prostate cancer. After MMAI results were incorporated into shared decision-making, use of the biomarker produced a 20.7% net reduction in ADT recommendations, with follow-up ongoing to assess clinical outcomes.

Another study evaluated MMAI in 173 patients with high- or very high-risk localized prostate cancer from the Phase III POP-RT trial in India. Among patients classified as MMAI high risk, whole-pelvis radiotherapy reduced five-year distant metastasis to 2%, compared with 17% for prostate-only radiotherapy, suggesting the biomarker may help identify patients who benefit from broader radiation treatment.

Additional research compared more than 20,000 commercial MMAI biopsy test results with outcomes from nearly 20,000 patients in the multinational STAR-CAP cohort. Predicted 10-year risks of distant metastasis and prostate cancer-specific mortality were generally similar to observed outcomes across established clinical risk groups, supporting the model’s performance outside its original validation studies.

In another study, transcriptomic analysis of 90 native African, African American, and European American patients showed that higher MMAI scores were associated with similar gene expression patterns linked to more aggressive prostate cancer. These included pathways involved in tumor growth and metastasis, suggesting that the biomarker captures related biological signals across diverse populations.

Separate data from NRG/RTOG post-radical prostatectomy Phase III trials showed that MMAI’s prognostic accuracy remained consistent across racial and age groups. Investigators reported no evidence that either factor introduced bias into its risk assessments, adding to findings supporting the platform’s performance across different patient populations.

Artera’s MMAI approach combines digitized histopathology images with clinical data to assess cancer aggressiveness and predict treatment benefit. The platform has been validated in multiple Phase III randomized trials and is available in several versions. Artera has also received U.S. FDA authorization for ArteraAI Prostate and clearance for ArteraAI Breast.

“We believe the future of cancer care is one where the patient’s unique biology and risk increasingly inform personalized treatment decisions,” said Andre Esteva, CEO and Co-founder of Artera. “These findings demonstrate the potential of Artera's platform to deliver on this vision by providing consistent, data-backed insights across diverse populations, helping clinicians better tackle some longstanding questions in medicine today."

Related Links
Artera


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Connectivity Solution
EKF Link
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.